Literature DB >> 26948292

Validating endpoints for therapeutic trials in fecal incontinence.

J Noelting1, A R Zinsmeister2, A E Bharucha1.   

Abstract

BACKGROUND: A 50% or greater reduction in the frequency of fecal incontinence (FI) recorded with daily bowel diaries is the primary endpoint in clinical trials of FI. Whether this difference is clinically important is unknown. The relationship between FI symptoms recorded with daily and weekly instruments is unknown. The contribution of psychological factors to quality of life (QOL) in FI is unclear.
METHODS: Fecal incontinence severity was assessed with daily bowel diaries and periodic questionnaires (fecal incontinence severity score [FISS], FIQOL, 36-Item Short Form Health Survey [SF-36], and hospital anxiety and depression scales) for 4 weeks before and during double-blind randomization to placebo or clonidine in 44 women with FI. The reduction in FI frequency was compared to the minimal clinically important difference (MCID) computed from the FISS. Endpoints of FI were compared between daily and weekly diaries. KEY
RESULTS: The FISS exceeded the MCID in 75% and 83% of patients in whom the FI frequency declined by 50-74% and ≥75% respectively. Parameters of FI measured with daily and weekly instruments were significantly correlated. The daily parameters explained 71% of the inter-patient variation in the FISS. The SF-36 health scores, rather than the FISS rating, explained a majority of the inter-subject variation in FIQOL. CONCLUSIONS & INFERENCES: Most patients who report a ≥50% reduction in FI frequency experience a clinically important improvement. Weekly questionnaires accurately assess the severity of FI. Self-reported physical and mental health explained a greater proportion of the variance in FIQOL than FI symptom severity.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  bowel diaries; endpoints; fecal incontinence; quality of life

Mesh:

Substances:

Year:  2016        PMID: 26948292      PMCID: PMC4956545          DOI: 10.1111/nmo.12809

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  33 in total

1.  Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence.

Authors:  T H Rockwood; J M Church; J W Fleshman; R L Kane; C Mavrantonis; A G Thorson; S D Wexner; D Bliss; A C Lowry
Journal:  Dis Colon Rectum       Date:  2000-01       Impact factor: 4.585

2.  Clinical significance of patient-reported questionnaire data: another step toward consensus.

Authors:  Jeff A Sloan; David Cella; Ron D Hays
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

3.  Prevalence and burden of fecal incontinence: a population-based study in women.

Authors:  Adil E Bharucha; Alan R Zinsmeister; G Richard Locke; Barbara M Seide; Kimberly McKeon; Cathy D Schleck; L Joseph Melton
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

4.  Prospective comparison of faecal incontinence grading systems.

Authors:  C J Vaizey; E Carapeti; J A Cahill; M A Kamm
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

5.  Incontinence: an underappreciated problem in obesity and bariatric surgery.

Authors:  Adil E Bharucha
Journal:  Dig Dis Sci       Date:  2010-09       Impact factor: 3.199

6.  Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence: the fecal incontinence severity index.

Authors:  T H Rockwood; J M Church; J W Fleshman; R L Kane; C Mavrantonis; A G Thorson; S D Wexner; D Bliss; A C Lowry
Journal:  Dis Colon Rectum       Date:  1999-12       Impact factor: 4.585

7.  Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement.

Authors:  William E Whitehead; Olafur S Palsson; Rona L Levy; Andrew D Feld; Michael VonKorff; Marsha Turner
Journal:  Am J Gastroenterol       Date:  2006-05       Impact factor: 10.864

8.  Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation.

Authors:  Ghislain Devroede; Chad Giese; Steven D Wexner; Anders Mellgren; John A Coller; Robert D Madoff; Tracy Hull; Katherine Stromberg; Sudha Iyer
Journal:  Female Pelvic Med Reconstr Surg       Date:  2012 Mar-Apr       Impact factor: 2.091

9.  Prevalence of and factors associated with fecal incontinence in a large community study of older individuals.

Authors:  Carline R Quander; Martha Clare Morris; Joshua Melson; Julia L Bienias; Denis A Evans
Journal:  Am J Gastroenterol       Date:  2005-04       Impact factor: 10.864

10.  Fecal incontinence in US adults: epidemiology and risk factors.

Authors:  William E Whitehead; Lori Borrud; Patricia S Goode; Susan Meikle; Elizabeth R Mueller; Ashok Tuteja; Alison Weidner; Milena Weinstein; Wen Ye
Journal:  Gastroenterology       Date:  2009-05-04       Impact factor: 22.682

View more
  11 in total

Review 1.  A systematic review of English language patient-reported outcome measures for use in urogynaecology and female pelvic medicine.

Authors:  Thomas G Gray; Holly Vickers; Priyanka Krishnaswamy; Swati Jha
Journal:  Int Urogynecol J       Date:  2021-05-26       Impact factor: 2.894

2.  Cortico-anorectal, Spino-anorectal, and Cortico-spinal Nerve Conduction and Locus of Neuronal Injury in Patients With Fecal Incontinence.

Authors:  Xuelian Xiang; Tanisa Patcharatrakul; Amol Sharma; Rachael Parr; Shaheen Hamdy; Satish S C Rao
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-10       Impact factor: 11.382

Review 3.  Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders.

Authors:  Adil E Bharucha; Satish S C Rao; Andrea S Shin
Journal:  Clin Gastroenterol Hepatol       Date:  2017-08-22       Impact factor: 11.382

4.  Relationship between symptoms and quality of life in fecal incontinence.

Authors:  K Bedard; S Heymen; O S Palsson; A E Bharucha; W E Whitehead
Journal:  Neurogastroenterol Motil       Date:  2017-11-02       Impact factor: 3.598

Review 5.  Faecal incontinence in adults.

Authors:  Adil E Bharucha; Charles H Knowles; Isabelle Mack; Allison Malcolm; Nicholas Oblizajek; Satish Rao; S Mark Scott; Andrea Shin; Paul Enck
Journal:  Nat Rev Dis Primers       Date:  2022-08-10       Impact factor: 65.038

Review 6.  Endpoints for therapeutic interventions in faecal incontinence: small step or game changer.

Authors:  S S C Rao
Journal:  Neurogastroenterol Motil       Date:  2016-08       Impact factor: 3.598

7.  Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review.

Authors:  Ferdinando D'Amico; Steven D Wexner; Carolynne J Vaizey; Célia Gouynou; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2020-07-17       Impact factor: 4.623

8.  Translumbosacral Neuromodulation Therapy Is a Promising Option for Fecal Incontinence.

Authors:  Adil E Bharucha; Nicholas R Oblizajek
Journal:  Am J Gastroenterol       Date:  2021-01-01       Impact factor: 12.045

9.  Characteristics Associated With Clinically Important Treatment Responses in Women Undergoing Nonsurgical Therapy for Fecal Incontinence.

Authors:  Holly E Richter; J E Jelovsek; P Iyer; R G Rogers; I Meyer; D K Newman; M S Bradley; I Harm-Ernandes; K Y Dyer; K Wohlrab; D Mazloomdoost; M G Gantz
Journal:  Am J Gastroenterol       Date:  2020-01       Impact factor: 12.045

10.  Translumbosacral Neuromodulation Therapy for Fecal Incontinence: A Randomized Frequency Response Trial.

Authors:  Satish S C Rao; Xuelian Xiang; Amol Sharma; Tanisa Patcharatrakul; Yun Yan; Rachael Parr; Deepak Ayyala; Shaheen Hamdy
Journal:  Am J Gastroenterol       Date:  2021-01-01       Impact factor: 12.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.